Fundraising Fox
/Companies
Sign in

Nuntius Therapeutics

YC W21

London, GB · Founded 2021 · 2 employees · 7 known investors

Find your way into Nuntius Therapeutics

Sign up to see every warm intro you have to Nuntius Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Nuntius Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Nuntius develops programmable nanocarriers for drug delivery that can target tissues beyond the liver and utilize machine learning to optimize carrier performance. The company serves pharmaceutical and biotech organizations developing targeted therapeutics.

AI & Machine LearningBiotechDeep TechHealthtechGene TherapyNanomedicineUnited KingdomEuropePartly Remote

Founders & leadership· Y Combinator alumni (W21)

Nuntius Therapeutics was founded in 2021 by Benita Nagel and Albert Kwok.

BNBenita Nagel
Benita NagelFounder
AKAlbert Kwok
Albert KwokCo-Founder and CSOAlbert Kwok has 20+ years of experience in gene and cell therapy, vaccines, oncology, immunology, neurology, and rare and cardiometabolic diseases, and serves as a healthcare investor. He is the founder of Nuntius Therapeutics, which develops programmable nanocarriers for targeted drug delivery.

Investors · 7

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

Asymmetry VenturesreportedRichmond · $125K – $500K

How we know: Y Combinator's founder network · Not right? Tell us

FoundersXreportedPalo Alto

How we know: Y Combinator's founder network · Not right? Tell us

Harvard Management CompanyreportedAllston

How we know: Y Combinator's founder network · Not right? Tell us

Nadav RosenbergreportedCanterbury

How we know: Y Combinator's founder network · Not right? Tell us

UNCOMMON DENOMINATORreportedNew York

How we know: Y Combinator's founder network · Not right? Tell us

Related companies · 6

NuntiusNuntius builds tools to ensure AI models comply with specified constraints and behave reliably in commercial applications.
Sixfold BioscienceSixfold develops RNA delivery technology for the biotech industry. The company was founded by an oncologist and plant scientist and focuses on advancing RNA-based therapeutic approaches through proprietary delivery methods.
Rejuvenation Technologies Inc.Rejuvenation develops proprietary mRNA and lipid nanoparticle technology to safely lengthen telomeres in human cells, targeting cellular aging and diseases caused by short telomeres including pulmonary fibrosis, liver disease, and bone marrow failure.
NanograbNanograb develops gene therapy delivery systems using artificial intelligence to identify peptide-nanoparticle combinations that transport genetic medicines to targeted cells and tissues.
Indee LabsIndee Labs develops Hydropore™, a non-viral microfluidic technology for delivering molecules, nucleic acids, proteins, and gene-editing complexes into immune cells for engineered cell therapy research and manufacturing. The platform enables rapid production of high-quality T-cell immunotherapies and other cell therapies with preserved cell function.
64x Bio64x develops infrastructure and manufacturing systems for next-generation medicines, focusing on genetic engineering, cell line development, and computational biology to enable scalability of advanced therapies.

Companies working in the same space as Nuntius Therapeutics.

Legal entities · 1

corporate structure
Nuntius Therapeutics, Inc.

Companies House · registry record

View on Companies House ↗
Registered name
NUNTIUS THERAPEUTICS LIMITED
Company number
13130725
Status
Active
Company type
Private limited company
Incorporated
13 Jan 2021
Registered office
Unit 23 The Cobalt Building, Lower Pemberton, Ashford, Kent, TN25 4BF
Nature of business (SIC)
72110 — Research and experimental development on biotechnology
Accounts
last made up to 31 Dec 2024 · next due 30 Sept 2026
Confirmation statement
last made up to 12 Jan 2026 · next due 26 Jan 2027

Current officers · 2

  • Ngai Ping Albert Kwok — director, appointed 13 Jan 2021
  • Benita Nagel — director, appointed 13 Jan 2021

Source: Companies House public register · retrieved 24 Jul 2026. Contains public sector information licensed under the Open Government Licence v3.0.

Frequently asked questions

What does Nuntius Therapeutics do?
Nuntius develops programmable nanocarriers for drug delivery that can target tissues beyond the liver and utilize machine learning to optimize carrier performance. The company serves pharmaceutical and biotech organizations developing targeted therapeutics.
Who founded Nuntius Therapeutics?
Nuntius Therapeutics was founded by Benita Nagel, Albert Kwok in 2021.
Who are Nuntius Therapeutics's investors?
Nuntius Therapeutics's investors include Backed, Y Combinator, Asymmetry Ventures, FoundersX, Harvard Management Company, Nadav Rosenberg, UNCOMMON DENOMINATOR.
Where is Nuntius Therapeutics headquartered?
Nuntius Therapeutics is headquartered in London, GB.